bb 2121

Drug Profile

bb 2121

Alternative Names: Anti-BCMA CAR T cells - bluebird bio/Celgene; BB-2121; bb2121

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator bluebird bio
  • Developer bluebird bio; Celgene Corporation
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 11 Dec 2017 Phase-II clinical trials in Multiple myeloma (Second-line therapy or greater, Refractory metastatic disease, Late-stage disease) in USA (IV)
  • 10 Dec 2017 Updated efficacy and adverse events data from the phase I CRB-401 trial in Multiple myeloma released by Celgene and bluebird bio
  • 16 Nov 2017 bb 2121 receives Breakthrough Therapy status for Multiple myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top